CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $6.60 and traded as high as $7.89. CryoPort shares last traded at $7.54, with a volume of 361,022 shares traded.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on CYRX shares. BTIG Research dropped their price target on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of CryoPort in a research report on Thursday, May 8th. Guggenheim restated a "buy" rating and set a $10.00 price objective on shares of CryoPort in a research note on Wednesday, April 16th. Stephens began coverage on CryoPort in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price objective for the company. Finally, Morgan Stanley decreased their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.63.
View Our Latest Research Report on CryoPort
CryoPort Stock Performance
The business has a 50 day simple moving average of $7.03 and a 200 day simple moving average of $6.58. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $364.50 million, a PE ratio of -3.11 and a beta of 1.88.
CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The company had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. Equities research analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.
Insiders Place Their Bets
In other CryoPort news, insider Edward J. Zecchini sold 51,500 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total value of $352,260.00. Following the completion of the sale, the insider directly owned 90,411 shares in the company, valued at approximately $618,411.24. This trade represents a 36.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 16,344 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $7.06, for a total value of $115,388.64. Following the completion of the sale, the chief executive officer owned 912,419 shares of the company's stock, valued at approximately $6,441,678.14. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 490,447 shares of company stock valued at $3,337,198. 10.00% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its stake in shares of CryoPort by 23.8% in the first quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock worth $476,000 after purchasing an additional 15,036 shares during the last quarter. Graham Capital Management L.P. raised its stake in shares of CryoPort by 24.9% in the fourth quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock worth $221,000 after purchasing an additional 5,667 shares during the last quarter. Lazard Asset Management LLC purchased a new position in shares of CryoPort in the fourth quarter worth about $51,000. ProShare Advisors LLC purchased a new position in shares of CryoPort in the fourth quarter worth about $95,000. Finally, CWM LLC raised its stake in shares of CryoPort by 1,437.0% in the first quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after purchasing an additional 10,591 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.
About CryoPort
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading
Before you consider CryoPort, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.
While CryoPort currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
